Guidance on the use of paclitaxel in the treatment of ovarian cancer
Issued: January 2003
Table of contents
Important information about this guidance 1 Guidance 2 Clinical need and practice 3 The technology 4 Evidence 5 Implications for the NHS 6 Further research 7 Implementation 8 Related guidance 9 Review of guidance Appendix A. Appraisal Committee members Appendix B. Sources of evidence considered by the Committee Appendix C. Patient information. Guidance on the use of paclitaxel in the treatment of ova... Appendix D. Detail on criteria for audit of the use of paclitaxel in the treatment of wome...This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta55
Important information about this guidance
This guidance replaces 'Ovarian cancer – taxanes' (NICE Technology Appraisal Guidance No 3) issued in May 2000.
This guidance has been partially updated by 'Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (review)' (NICE technology appraisal guidance 91 [TA91]. The recommendations that have been updated are indicated in section 1 below.
This guidance was developed using the NICE single technology appraisals process: www.nice.org.uk/aboutnice/howwework/devnicetech/developing_nice_technology_appraisals.jsp